HighTower Advisors
CNCR

HighTower Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

HighTower Advisors’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7,140
Closed -$207K – 2260
2018
Q1 		$207K Buy
+7,140
New +$202K ﹤0.01% 1860

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

HighTower Advisors's CNCR Position: Q2 2018 in Review

HighTower Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2018, closing a stake of 7,140 shares — an estimated $207K sold.

HighTower Advisors first reported a position in CNCR in Q1 2018 and held it in 1 quarter. The position peaked at $207K in Q1 2018. 28 funds tracked by Wall St. Rank hold CNCR as of Q2 2018.

  • HighTower Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2018 after selling out during the quarter.
  • HighTower Advisors sold 7,140 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2018, an estimated $207K.
  • HighTower Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2018 and held it in 1 quarter.
  • HighTower Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $207K in Q1 2018.
  • 28 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2018.

Based on HighTower Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.